Analytical Data
-
Gene name
IKZF1
- Application
-
Alternative Names
Ikaros family zinc finger protein 1 (Lymphoid transcription factor LyF-1) (IK1) (IKAROS) (LYF1) (ZNFN1A1)
-
Species
Human
-
Source
E. coli
-
Tag
N- His-Avi
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q13422
-
Expression Region
1-477aa
-
Molecular Weight
56.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IKZF1, also known as Ikaros, is a key transcription factor that plays a critical role in hematopoiesis and the development of the immune system. Abnormalities in the IKZF1 gene, such as deletions or mutations, have been associated with various hematological malignancies, particularly in acute lymphoblastic leukemia (ALL). Research into IKZF1 has revealed its essential function in regulating the differentiation and proliferation of B and T lymphocytes, and it acts as a tumor suppressor in hematopoietic cells. Recombination of IKZF1 protein has become a focal point in understanding its structure-function relationships and the mechanisms by which it contributes to leukemogenesis. By generating recombinant IKZF1 proteins, researchers can investigate the impact of specific mutations on its activity, identify potential binding partners, and elucidate the pathways in which it is involved. This research is pivotal not only for understanding the pathophysiology of related malignancies but also for developing targeted therapies that can harness the functions of IKZF1 to improve therapeutic outcomes in patients with IKZF1-associated diseases. Through these studies, scientists aim to uncover novel insights into the regulatory networks governing immune cell development and function, ultimately leading to advances in cancer treatment and immunotherapy strategies.
